Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Non protein nitrogen

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Non protein nitrogen. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-003971-30 Sponsor Protocol Number: 0804/TO Start Date*: 2009-04-02
    Sponsor Name:Univ.-Prof. Dr. Karlheinz Tscheliessnigg
    Full Title: Klinische Studie zur Überprüfung der Auswirkungen einer präoperativen Verabreichung von Glutamin und/oder Omega-3-Fettsäuren auf das Inflammationsgeschehen nach aortokoronaren Bypassoperationen
    Medical condition: Indikationsstellung für eine aortokoronare Bypassoperation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000333-13 Sponsor Protocol Number: APHP200046 Start Date*: Information not available in EudraCT
    Sponsor Name:APHP DRCI
    Full Title: Efficacy of the nonavalent HPV vaccine in the treatment of difficult-to-treat palmo-plantar warts
    Medical condition: Vaccination by nonavalent vaccine against HPV could lead to a complete resolution of difficult-to-treat palmo-plantar warts in patients of more than 15 years and 3 months of age
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001972-46 Sponsor Protocol Number: SKNt-001-CP4 Start Date*: 2019-05-14
    Sponsor Name:Fresenius Kabi Deutschland GmbH
    Full Title: Reaching Protein Target with SmofKabiven® extra Nitrogen Versus Olimel N9E: A Prospective, Randomised, Active-controlled, Patient-blinded, Multicentre Clinical Trial During the Early Phase of Acute...
    Medical condition: Parenteral nutrition (PN) when oral or enteral nutrition (ON or EN) is impossible, insufficient, or contraindicated in the early phase of critical illness
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10051284 Parenteral nutrition PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001693-27 Sponsor Protocol Number: 05/Q1606/30 Start Date*: 2005-06-24
    Sponsor Name:Oxford Radcliffe Hospitals NHS Trust
    Full Title: Pilot Effectiveness of Randomised Mandatory Insulin Therapy
    Medical condition: Those admitted to the Intensive Care Unit for treatment and likely to remain on the unit for longer than 5 days.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-002329-56 Sponsor Protocol Number: FISIO Start Date*: 2021-10-19
    Sponsor Name:Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC)
    Full Title: Exploratory study to evaluate the efficacy and safety of nutritionally administering 1.5 g protein/kg/day vs. 1.0 g protein/kg/day in the catabolic phase of the critically ill patient on mechanical...
    Medical condition: Acquired Weakness in the Intensive Care Unit (DAUCI) of the critically ill patient.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10077255 Intensive care unit acquired weakness PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004727-36 Sponsor Protocol Number: NR 8230-3/2004 Start Date*: 2005-02-10
    Sponsor Name:Charles University, 3rd Faculty of Medicine
    Full Title: Influence of low-dose i.v. growth hormone treatment together with glutamine supplementation in late-phase critically ill patient after multiple injury. A pilot study.
    Medical condition: Prolonged phase of critical illness after severe multiple trauma
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002436-82 Sponsor Protocol Number: EC11-441 Start Date*: 2012-12-13
    Sponsor Name:Isabel Pinilla Lozano
    Full Title: Melatonin effects on visual and sleep patterns anomalies in subjects diagnosed with Retinitis Pigmentosa
    Medical condition: To evaluate the sleep quality in patients with Retinitis Pigmentosa
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005993-12 Sponsor Protocol Number: S245.4.012 Start Date*: 2009-06-18
    Sponsor Name:Solvay Pharmaceutical GmbH
    Full Title: A three month double-blind, randomized, placebo-controlled, parallel group, multi-center study with Creon® 25.000 MMS? in subjects after an attack of acute pancreatitis suffering from pancreatic ex...
    Medical condition: Pancreatic exocrine insufficiency after acute pancreatitis. Insuficiencia pancreática exocrina tras un episodio de pancreatitis aguda.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033628 Pancreatic insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004854-29 Sponsor Protocol Number: S245.4.008 Start Date*: 2007-09-21
    Sponsor Name:Abbott Products GmbH
    Full Title: One week double-blind, randomized, placebo-controlled, parallel-group, multi-center study with Creon® 25000 Minimicrospheres™ in subjects with pancreatic exocrine insufficiency after pancreatic sur...
    Medical condition: Pancreatic Exocrine Insufficiency
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033628 Pancreatic insufficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-000172-19 Sponsor Protocol Number: 15-124 Start Date*: 2017-02-20
    Sponsor Name:RWTH Aachen University for the Medical Faculty, represented by Center for Transitional & Clinical Research Aachen (CTC-A
    Full Title: Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients with Type 2 Diabetes
    Medical condition: Patients with Type 2 diabetes mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002695-45 Sponsor Protocol Number: 15-156 Start Date*: 2018-05-16
    Sponsor Name:RWTH Aachen University represented by the Rector, himself, represented by the Dean of the Medical Faculty
    Full Title: Effect of Empagliflozin on Cardiac Output in Patients with Acute Heart Failure (EMPA Acute Heart Failure)
    Medical condition: Patients with acute heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016703-35 Sponsor Protocol Number: NAPMSv3.2 Start Date*: 2010-01-08
    Sponsor Name:Dansk Multipel Sclerose Center
    Full Title: Natalizumabbehandling af progressiv multipel sklerose
    Medical condition: Secondary progressive multiple sclerosis and primary progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10063400 Secondary progressive multiple sclerosis LLT
    12.0 10063401 Primary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-001045-14 Sponsor Protocol Number: SAF001 Start Date*: 2013-04-22
    Sponsor Name:Promethera Biosciences
    Full Title: SAF 001: A long-term safety follow-up study of patients suffering from Urea Cycle disorders (UCD) or Crigler-Najjar Syndrome (CN) having received infusions of HepaStem.
    Medical condition: Crigler-Najjar syndrome is associated with a complete or partial hepatic deficit of bilirubin glucuronosyltransferase activity and is apparent during the neonatal period by intense jaundice. The ur...
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004850 10021601 Inborn error of metabolism NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000375-42 Sponsor Protocol Number: S339.2.001 Start Date*: 2008-02-21
    Sponsor Name:Solvay Pharmaceuticals GmbH
    Full Title: A multi-center, double-blind, parallel-design, randomized, placebo-controlled, dose-ranging study to assess the efficacy and safety of oral recombinant microbial lipase (SLV339) in subjects with pa...
    Medical condition: Pancreatic exocrine insufficiency due to chronic pancreatitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009093 Chronic pancreatitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) SE (Prematurely Ended) HU (Prematurely Ended) CZ (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2021-002927-39 Sponsor Protocol Number: BOOST_TX/RESCUE_TX Start Date*: 2021-06-13
    Sponsor Name:Medical University of Vienna
    Full Title: Preventive strategies against SARS-CoV-2 in kidney transplant recipients: Intervention A – vaccination: Single blinded randomized controlled trial on BNT162b2 or mRNA-1273 (mRNA) vs Ad26COVS1 or C...
    Medical condition: Intervention A - vaccination Patients following kidney transplant recipients who do not have an adequate immune response against SARS-CoV-2 following two doses of an mRNA vaccine Substudy A: kidne...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021860-13 Sponsor Protocol Number: BIA-91067-301 Start Date*: 2010-11-11
    Sponsor Name:BIAL - Portela & Ca, S.A.
    Full Title: EFFICACY AND SAFETY OF BIA 9-1067 IN IDIOPATHIC PARKINSON’S DISEASE PATIENTS WITH “WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA PLUS A DOPA DECARBOXYLASE INHIBITOR (DDCI): A DOUBLE-BLIND, RANDOMIS...
    Medical condition: Adjunct to levodopa (L-DOPA)/DDCI for use in patients with Parkinson’s disease (PD) and end-of-dose motor fluctuations.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) AT (Completed) LV (Completed) DE (Completed) ES (Completed) PT (Completed) CZ (Completed) SK (Completed) BG (Completed) RO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003866-16 Sponsor Protocol Number: AP REN 01-01 Start Date*: 2009-03-03
    Sponsor Name:AM-Pharma B.V.
    Full Title: A Phase-II, double-blind, randomized, placebo-controlled proof of concept study on the safety and early efficacy of Alkaline Phosphatase in sepsis patients with Renal Failure.
    Medical condition: Sepsis with Renal Failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040050 Sepsis NOS LLT
    9.1 10038435 Renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005140-18 Sponsor Protocol Number: RAME-01 Start Date*: 2015-11-12
    Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA
    Full Title: Diagnostic and clinical value of fused 64CuCl2-PET/MRI in prostate cancer relapse. Comparison with multiparametric MRI (mMRI) and 18F-Choline-PET/MRI
    Medical condition: Prostate cancer patients who showed biochemical relapse after surgery or first-line treatment with radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10038604 Reproductive system and breast disorders SOC
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001081-38 Sponsor Protocol Number: ARCT-810-03 Start Date*: 2021-12-23
    Sponsor Name:Arcturus Therapeutics, Inc.
    Full Title: Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult ...
    Medical condition: Ornithine transcarbamylase deficiency
    Disease: Version SOC Term Classification Code Term Level
    26.0 100000004850 10013373 Disorders of urea cycle metabolism LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed) SE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000674-58 Sponsor Protocol Number: AL1011av Start Date*: 2011-07-28
    Sponsor Name:Allergopharma Joachim Ganzer KG
    Full Title: Double-blind, placebo controlled study to investigate the dose response of an allergoid preparation of Phleum pratense in adult patients with IgE mediated allergic Rhinitis / Rhinoconjunctivitis wi...
    Medical condition: ICD classification code: J 45.0 and J 30.1
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039087 Rhinitis allergic NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 10:32:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA